Preterm birth-even late preterm birth-increases the chances that the child will be prescribed medication for attention-deficit/hyperactivity disorder later in life.
Preterm birth-even late preterm-increases the chances that the child will be prescribed medication for attention-deficit/hyperactivity disorder (ADHD) later in life, according to the results of a study from Sweden.
Researchers gathered and analyzed data from a Swedish database on more than 1 million children ages 6 to 19 years; 7,506 of them had taken ADHD drugs. The most commonly purchased was methylphenidate (87.8%), followed by atomoxetine (9.2%), and amphetamine (3%).
The researchers found step-wise increases in odds ratios for having taken ADHD medication with increasing degree of prematurity at birth. Compared with infants born at 39 to 41 weeks' gestation, those born at 23 to 28 weeks had the highest risk for subsequently taking ADHD drugs with an odds ratio [OR] of 2.1 (1.4-2.7); 15 of every 1,000 babies born between 23 and 28 weeks went on to take ADHD drugs during school years compared with 6 of 1,000 born full-term.
The researchers also found that social adversity, as expressed by low maternal education, modifies the risk for ADHD in moderately preterm birth. They emphasized that their study gathered data on children prescribed ADHD drugs, not those diagnosed with the disorder.
Lindström K, Lindblad F, Hjern A. Preterm birth and attention-deficit/hyperactivity disorder in schoolchildren. Pediatrics. 2011;127(5):858-865.
Hormone therapy safety: Study finds potential benefits for senior women
April 24th 2024A recent large-scale study challenged age-related concerns, suggesting hormone therapy may offer safety and even benefits for menopausal women aged over 65 years, aligning with The Menopause Society's 2022 Position Statement.
Read More
Hyperoxygenation use not linked to neonatal outcomes
April 23rd 2024Recent research evaluated the impact of maternal hyperoxygenation on neonatal Apgar scores, revealing no significant enhancement in outcomes among women with pathologic fetal heart rate tracing and suggesting limited efficacy of hyperoxygenation therapy in this context.
Read More
Study finds antihypertensive treatment reduces uterine fibroids risk
April 23rd 2024A recent study revealed that patients with untreated or new-onset hypertension face elevated chances of uterine fibroid diagnosis, underscoring the potential of antihypertensive therapy in mitigating this risk among midlife individuals.
Read More